|
Synonyms: GAP-134 | ZP-1609 | ZP1609
Compound class:
Synthetic organic
Comment: Danegaptide (GAP-134, and formerly ZP 1609) is an orally bioavailable gap-junction modifier that targets connexin-43. It is the successor molecule to rotigaptide which was intravenously administered. Like rotigaptide, danegaptide was initially intended for the treatment of chronic heart conditions such as ventricular arrhythmias and atrial fibrillation, but focus was diverted to the role of connexin-43 modulation in diabetic retinopathy.
|
|
|||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| Clinical studies of danegaptide (GAP-134, ZP 1609) in cardiovascular disease failed to find efficacy, and the development programme was terminated at phase 2. The drug was repurposed as a potential treatment for diabetic retinopathy, where it is proposed to reduce pathological retinal blood vessel leakage by stabilising connexin 43-containing tight junctions in the inner blood-retina barrier [1]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT01977755 | Phase 2 Clinical Proof-of-Concept Study of the Cardioprotective Properties of Danegaptide in ST Segment Elevation Myocardial Infarction | Phase 2 Interventional | Zealand Pharma | ||